Christina Baik, MD, MPH

Christina Baik, MD, MPH, discusses alectinib compared to crizotinib in the first-line setting for patients with ALK-positive lung cancer.

Christina Baik, MD, MPH, assistant professor, Seattle Cancer Care Alliance, Thoracic/Head and Neck, Department of Medicine, Division of Medical Oncology, University of Washington, discusses the efficacy of alectinib after first-line crizotinib in patients with ALK-positive lung cancer. Baik says alectinib generally works for about 8 months and is easy to take for patients.